Highlights
- Total Revenue (TTM)
- $257.55M
- Gross Profit (TTM)
- $179.88M
- EBITDA (TTM)
- $56.98M
- Year Range
- $0.00 - $3.87
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Eagle Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Eagle Pharmaceuticals Inc (EGRX) has returned -51.27% so far this year and -65.19% over the past 12 months. Over the last ten years, EGRX has returned -38.00% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Eagle Pharmaceuticals Inc
- 1D
- 0.00%
- 1M
- 127.40%
- YTD
- -51.27%
- 6M
- -87.37%
- 1Y
- -65.19%
- 3Y*
- -77.09%
- 5Y*
- -61.79%
- 10Y*
- -38.00%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Feb 12, 2014, EGRX's average daily return is +0.74%, while the average monthly return is +1.30%. At this rate, your investment would double in approximately 4.5 years.
Historically, 51% of months were positive and 49% were negative. The best month was Mar 2026 with a return of +127.4%, while the worst month was Oct 2024 at -83.9%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.
On a daily basis, EGRX closed higher 47% of trading days. The best single day was Mar 17, 2026 with a return of +900.0%, while the worst single day was Mar 16, 2026 at -99.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -64.29% | -40.00% | 127.40% | -51.27% | |||||||||
| 2025 | 60.00% | 50.00% | -18.33% | 100.00% | -3.06% | 52.63% | 27.24% | -16.26% | -12.62% | -74.07% | -28.57% | 40.00% | 40.00% |
| 2024 | 12.05% | 0.00% | -10.58% | -21.95% | -15.16% | 61.38% | -13.93% | 6.64% | -27.43% | -83.91% | 18.33% | -29.58% | -90.44% |
| 2023 | 16.11% | -17.50% | 1.32% | -1.02% | -26.10% | -6.31% | 6.79% | -18.35% | -6.96% | -12.94% | -57.39% | -10.60% | -82.11% |
| 2022 | -9.78% | 3.16% | 4.43% | -10.83% | 5.82% | -4.86% | -10.65% | -17.46% | -19.38% | 19.11% | 15.41% | -19.52% | -42.60% |
| 2021 | 0.21% | -4.65% | -6.20% | -2.18% | -2.96% | 8.03% | 8.64% | 14.77% | 4.52% | -6.11% | -8.96% | 6.80% | 9.34% |
Benchmark Metrics
Eagle Pharmaceuticals Inc has an annualized alpha of 491.60%, beta of 0.73, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 13, 2014.
- This stock participated in 145.97% of S&P 500 Index downside but only -17.26% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 491.60%
- Beta
- 0.73
- R²
- 0.00
- Upside Capture
- -17.26%
- Downside Capture
- 145.97%
Return for Risk
Risk / Return Rank
EGRX ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Eagle Pharmaceuticals Inc (EGRX) and compare them to a chosen benchmark (S&P 500 Index).
| EGRX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.05 | 0.90 | -0.95 |
Sortino ratioReturn per unit of downside risk | 11.13 | 1.39 | +9.74 |
Omega ratioGain probability vs. loss probability | 3.35 | 1.21 | +2.14 |
Calmar ratioReturn relative to maximum drawdown | -0.61 | 1.40 | -2.01 |
Martin ratioReturn relative to average drawdown | -1.03 | 6.61 | -7.63 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore EGRX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Eagle Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eagle Pharmaceuticals Inc was 100.00%, occurring on Mar 16, 2026. The portfolio has not yet recovered.
The current Eagle Pharmaceuticals Inc drawdown is 99.66%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Aug 6, 2015 | 2667 | Mar 16, 2026 | — | — | — |
| -37.6% | Mar 10, 2014 | 52 | May 21, 2014 | 155 | Dec 31, 2014 | 207 |
| -16.56% | Jun 23, 2015 | 8 | Jul 2, 2015 | 7 | Jul 14, 2015 | 15 |
| -15.66% | Jan 12, 2015 | 4 | Jan 15, 2015 | 5 | Jan 23, 2015 | 9 |
| -14.8% | Mar 16, 2015 | 8 | Mar 25, 2015 | 5 | Apr 1, 2015 | 13 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Eagle Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Eagle Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |